Cerebral venous sinus thrombosis related to vaccine-induced immune thrombotic thrombocytopenia: First reported case in Vietnam

Hoang Bui Hai , Do Giang Phuc, Nguyen Thanh Chung, Tran Thi Kieu My, Le Thi Thanh Xuan, Michael M Dinh, Nguyen Lan Hieu

Nội dung chính của bài viết

Tóm tắt

Vaccination remains one of the most important public health interventions to control and mitigate the impacts of COVID-19 worldwide. A number of post-vaccination reactions have caused concern and are the cause of vaccine hesitancy. Vaccine-induced immune thrombotic thrombopenia (VITT) has been reported in several countries such as Norway at a rate of 1 per 26000 doses of the ChAdOx1 nCoV vaccine (AstraZeneca), 15 per 8 million doses of Ad26.COV2.S (Janssen; Johnson & Johnson) vaccines in the US. In Vietnam, 11.5 million doses of AstraZeneca vaccine have been administered since the commencement of a nation-wide vaccination program five months ago. We report the first case of cerebral venous thrombosis related to VITT which was promptly diagnosed and successfully treated with rivaroxaban alone. Thus, VITT is very rare in Vietnamese people vaccinated with the AstraZeneca vaccine in the prevention of COVD-19 infection.

Chi tiết bài viết

Tài liệu tham khảo

1. Lurie N, Saville M, Hatchett R, et al. Developing Covid-19 vaccines at pandemic speed. N Eng J Med. 2020;382:1969-73.
2. Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. The Lancet. 2020;396:467-478.
3. Madhi S.A., Baillie V., Cutland C.L., et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N Eng J Med. 2021;384:1885-98.
4. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet. 2021;397(10269):99-111.
5. Scully M, Singh D, Lown R, et al. Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination. N Eng J Med. 2021;384(23):2202-11.
6. Pavord S, Path FRC, Scully M, et al. Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis. N Eng J Med. 2021. DOI: 10.1056/NEJMoa2109908.
7. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N Engl J Med. 2021;384(20):2093-2101.
8. See I, Su JR, Lale A, et al. US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination. JAMA. 2021;325(24):2448.
9. Bousser MG. Cerebral venous thrombosis: an update. The Lancet Neuron. 2007;6(2):162-70.
10. Douxfils J, Favresse J, Dogne JM, et al. Hypotheses behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination. Thromb Res. 2021;203:163-171.
11. Saposnik G, Barinagarrementeria F, Brown RD, et al. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(4):1158.
12. McGonagle D, Marco G, Bridgewood C. Mechanisms of Immunothrombosis in Vaccine-Induced Thrombotic Thrombocytopenia (VITT) Compared to Natural SARS-CoV-2 Infection. Journal of Autoimmunity. 2021;121:102662.
13. Lin W, Aislinn O,Peng H, et al. SARS-CoV-2 and cardiovascular complications: From molecular mechanisms to pharmaceutical management. Biochemical pharmacology. 2020;178:114114.
14. Khelfaoui H, Harkati D, Saleh BA. Molecular docking, molecular dynamics simulations and reactivity, studies on appreoved drugs library targeting ACE2 and SARS-CoV-2 binding with ACE2. Journal of biomolecular Structure &Dynamics. 2020;1-17.